Published in Chem Soc Rev on August 13, 2004
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology (2009) 1.23
Application of activity-based probes to the study of enzymes involved in cancer progression. Curr Opin Genet Dev (2008) 1.17
Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem Biol Drug Des (2009) 1.11
Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res (2011) 1.06
Extracellular proteases as targets for drug development. Curr Protein Pept Sci (2009) 1.02
A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition. Chem Biol Drug Des (2009) 1.00
Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem (2010) 0.98
CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis. Oncogene (2011) 0.98
Non-invasive imaging of cysteine cathepsin activity in solid tumors using a 64Cu-labeled activity-based probe. PLoS One (2011) 0.97
Protease-sensitive fluorescent nanofibers. Bioconjug Chem (2007) 0.96
Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer. Int J Clin Exp Med (2011) 0.93
In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity. Mol Pharm (2011) 0.90
Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol Cell Proteomics (2012) 0.89
Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharmacol (2008) 0.87
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis (2013) 0.87
Conformational analyses of thiirane-based gelatinase inhibitors. Bioorg Med Chem Lett (2007) 0.82
Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res (2013) 0.81
Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes. Front Chem (2015) 0.80
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator. BMC Chem Biol (2006) 0.80
Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound. PLoS One (2014) 0.78
Anticancer effects of sweet potato protein on human colorectal cancer cells. World J Gastroenterol (2013) 0.77
Novel yeast bioassay for high-throughput screening of matrix metalloproteinase inhibitors. Appl Environ Microbiol (2011) 0.75
Quantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanofiber nanoelectrode arrays toward identification of cancer formation. Nanomedicine (2015) 0.75
Methanethiol Binding Strengths and Deprotonation Energies in Zn(II)-Imidazole Complexes from M05-2X and MP2 Theories: Coordination Number and Geometry Influences Relevant to Zinc Enzymes. J Phys Chem B (2015) 0.75
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev (2005) 4.48
Tackling antibiotic resistance. Nat Rev Microbiol (2011) 3.95
Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev (2003) 3.72
Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc Natl Acad Sci U S A (2006) 2.81
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev (2012) 1.96
Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J (2006) 1.93
Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res (2008) 1.88
Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem (2005) 1.83
How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci U S A (2013) 1.75
Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol (2004) 1.75
The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J Biol Chem (2004) 1.74
Ab initio QM/MM study of class A beta-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. J Am Chem Soc (2005) 1.67
Recent advances in MMP inhibitor design. Cancer Metastasis Rev (2006) 1.66
Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics (2008) 1.60
Bacterial cell-wall recycling. Ann N Y Acad Sci (2012) 1.60
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem (2003) 1.52
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. Antimicrob Agents Chemother (2009) 1.51
Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol (2006) 1.50
Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc (2008) 1.50
Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun (2003) 1.48
Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev (2003) 1.45
Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst (2002) 1.45
Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol (2002) 1.42
Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. Int J Cancer (2014) 1.39
Resistance to beta-lactam antibiotics and its mediation by the sensor domain of the transmembrane BlaR signaling pathway in Staphylococcus aureus. J Biol Chem (2003) 1.38
Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol (2012) 1.38
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res (2005) 1.36
The future of the β-lactams. Curr Opin Microbiol (2010) 1.36
High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 beta-lactamase. J Am Chem Soc (2002) 1.36
MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev (2008) 1.34
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A (2003) 1.34
Synthetic peptidoglycan substrates for penicillin-binding protein 5 of Gram-negative bacteria. J Org Chem (2004) 1.33
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol (2005) 1.32
Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry (2005) 1.32
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res (2005) 1.32
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer (2006) 1.32
Bacterial AmpD at the crossroads of peptidoglycan recycling and manifestation of antibiotic resistance. J Am Chem Soc (2009) 1.31
Activation of BlaR1 protein of methicillin-resistant Staphylococcus aureus, its proteolytic processing, and recovery from induction of resistance. J Biol Chem (2011) 1.30
Mechanistic characterization of the bifunctional aminoglycoside-modifying enzyme AAC(3)-Ib/AAC(6')-Ib' from Pseudomonas aeruginosa. Biochemistry (2007) 1.28
Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases. J Biol Chem (2009) 1.28
Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem (2013) 1.27
Structural insights into the bactericidal mechanism of human peptidoglycan recognition proteins. Proc Natl Acad Sci U S A (2007) 1.27
Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res (2007) 1.25
Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens. Biochemistry (2006) 1.25
Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane. FASEB J (2011) 1.25
Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime. Antimicrob Agents Chemother (2002) 1.23
Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc (2002) 1.23
Activation for catalysis of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus by bacterial cell wall. J Am Chem Soc (2005) 1.22
The importance of a critical protonation state and the fate of the catalytic steps in class A beta-lactamases and penicillin-binding proteins. J Biol Chem (2004) 1.22
Reactions of all Escherichia coli lytic transglycosylases with bacterial cell wall. J Am Chem Soc (2013) 1.21
Lytic transglycosylase MltB of Escherichia coli and its role in recycling of peptidoglycan strands of bacterial cell wall. J Am Chem Soc (2008) 1.21
Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferases. J Biol Chem (2009) 1.21
Synthesis of a fragment of bacterial cell wall. J Org Chem (2004) 1.20
Total synthesis of N-acetylglucosamine-1,6-anhydro-N-acetylmuramylpentapeptide and evaluation of its turnover by AmpD from Escherichia coli. J Am Chem Soc (2009) 1.19
Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc (2007) 1.19
The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J Am Chem Soc (2003) 1.18
Messenger functions of the bacterial cell wall-derived muropeptides. Biochemistry (2012) 1.17
Discrete steps in sensing of beta-lactam antibiotics by the BlaR1 protein of the methicillin-resistant Staphylococcus aureus bacterium. Proc Natl Acad Sci U S A (2006) 1.17
Three decades of the class A beta-lactamase acyl-enzyme. Curr Protein Pept Sci (2009) 1.17
Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol (2002) 1.15
X-ray crystal structure of the acylated beta-lactam sensor domain of BlaR1 from Staphylococcus aureus and the mechanism of receptor activation for signal transduction. J Am Chem Soc (2004) 1.15
Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem (2003) 1.14
TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J (2003) 1.13
Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem (2003) 1.13
Synthetic peptidoglycan motifs for germination of bacterial spores. Chembiochem (2010) 1.12
Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J Biol Chem (2002) 1.12
Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. J Am Chem Soc (2014) 1.11
Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem Biol Drug Des (2009) 1.11
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res (2010) 1.10
Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab (2009) 1.10
Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des (2007) 1.10
Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. J Am Chem Soc (2014) 1.10
Pharmacological stabilization of intracranial aneurysms in mice: a feasibility study. Stroke (2012) 1.10
Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener (2012) 1.10
Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol (2007) 1.09
Insertion of epicatechin gallate into the cytoplasmic membrane of methicillin-resistant Staphylococcus aureus disrupts penicillin-binding protein (PBP) 2a-mediated beta-lactam resistance by delocalizing PBP2. J Biol Chem (2010) 1.09
Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. J Am Chem Soc (2002) 1.08
Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci (2005) 1.08
Short alkylated peptoid mimics of antimicrobial lipopeptides. Antimicrob Agents Chemother (2010) 1.08
Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett (2005) 1.08
Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii. Chem Biol (2013) 1.08
Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity. J Biol Chem (2004) 1.07
A practical synthesis of nitrocefin. J Org Chem (2005) 1.07
Reactions of the three AmpD enzymes of Pseudomonas aeruginosa. J Am Chem Soc (2013) 1.06
Elucidation of the molecular recognition of bacterial cell wall by modular pneumococcal phage endolysin CPL-1. J Biol Chem (2007) 1.06
Crystal structures of penicillin-binding protein 6 from Escherichia coli. J Am Chem Soc (2009) 1.05